Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non–Small Cell Lung Cancer and Poor Performance Status-Reference-Cited by-同舟云学术

Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non–Small Cell Lung Cancer and Poor Performance Status

Published:2021-10-01 Issue:10 Volume:7 Page:1497
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Iyengar Puneeth¹²³,Zhang-Velten Elizabeth¹²³,Court Laurence⁴,Westover Kenneth¹²³,Yan Yulong¹²³,Lin Mu-Han¹²³,Xiong Zhenyu¹²³,Patel Mehul⁵,Rivera Douglas⁶,Chang Joe⁴,Saunders Mark⁷,Shivnani Anand⁸,Lee Andrew⁹,Hughes Randall¹²³,Gerber David¹²³,Dowell Jonathan¹²³,Gao Ang¹²³,Heinzerling John¹⁰,Li Ying¹¹,Ahn Chul¹²³,Choy Hak¹²³,Timmerman Robert¹²³

Affiliation:

1. Department of Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas

2. Department of Medical Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas

3. Department of Biostatistics, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas

4. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, Texas

5. Department of Radiation Oncology, Baylor Scott & White Memorial Hospital, Temple, Texas

6. Department of Radiation Oncology, Austin Cancer Center, Austin, Texas

7. Department of Radiation Oncology, Texas Oncology Tyler, Tyler

8. Department of Radiation Oncology, Texas Oncology Sherman, Sherman

9. Department of Radiation Oncology, Texas Center for Proton Therapy, Irving

10. Department of Radiation Oncology, Levine Cancer Institute, Atrium Heath, Charlotte, North Carolina

11. Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2783004/jamaoncology_iyengar_2021_oi_210049_1634002253.29876.pdf

Reference24 articles.

1. Cancer statistics, 2020.;Siegel;CA Cancer J Clin,2020

2. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer.;Aupérin;J Clin Oncol,2010

3. Effects of concomitant cisplatin and radiotherapy on inoperable non–small-cell lung cancer.;Schaake-Koning;N Engl J Med,1992

4. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.;Komaki;Int J Radiat Oncol Biol Phys,1997

5. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non–small-cell lung cancer: long-term follow-up of RTOG 92-04.;Komaki;Int J Radiat Oncol Biol Phys,2002

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma;Clinical and Translational Radiation Oncology;2024-11

2. “Mid-P strategy” versus “internal target volume strategy in locally advanced non small cell lung cancer: Clinical results from the randomized non-comparative phase II study Mid-P;Radiotherapy and Oncology;2024-10

3. Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-10

4. Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group;Cancers;2024-09-09

5. Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113–08113 LungTech Phase II Trial Results;Journal of Thoracic Oncology;2024-09